MEK1 inhibition in HSP90-based therapy was tested in some cancer entities, yielding additive to synergistic effects in, for example, non-small cell lung cancer [105] and melanoma [106], although a possible HSR abrogation again was not studied. The gene discussed is MAP2K1; the disease is non-small cell lung carcinoma.